Journal
ADVANCED DRUG DELIVERY REVIEWS
Volume 60, Issue 8, Pages 886-898Publisher
ELSEVIER
DOI: 10.1016/j.addr.2007.11.009
Keywords
polymer-drug conjugates; anticancer drugs; nanocarriers; paclitaxel; PG-TXL
Categories
Funding
- NCI NIH HHS [R29 CA074819-03, R29 CA074819-04S1, R29 CA74819, R29 CA074819-04, R29 CA074819-05S1, R29 CA074819-05] Funding Source: Medline
Ask authors/readers for more resources
Targeted drug delivery aims to increase the therapeutic index by making more drug molecules available at the diseased sites while reducing systemic drug exposure. In this update, we provide an overview of polymer-drug conjugates that have advanced into clinical trials. These systems use synthetic water-soluble polymers as the drug carriers. The preclinical pharmacology and recent data in clinical trials with poly(L-glutamic acid)-paclitaxel (PG-TXL) are discussed. This is followed by a summary of a variety of polymeric conjugates with chemotherapeutic agents. Results from early clinical trials of these polymer-drug conjugates have demonstrated several advantages over the corresponding parent drugs, including fewer side effects, enhanced therapeutic efficacy, ease of drug administration, and improved patient compliance. Collectively, these data wan-ant further clinical development of polymer-drug conjugates as a new class of anticancer agents. (C) 2008 Elsevier B.V. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available